Merck & Co., Inc. Stock price

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 04:01:04 2024-03-18 pm EDT 5-day change 1st Jan Change
121.4 USD -0.07% Intraday chart for Merck & Co., Inc. -1.08% +11.39%
Sales 2024 * 63.74B Sales 2025 * 67.94B Capitalization 308B
Net income 2024 * 19.92B Net income 2025 * 22.25B EV / Sales 2024 * 5.12 x
Net Debt 2024 * 18.9B Net Debt 2025 * 7.72B EV / Sales 2025 * 4.64 x
P/E ratio 2024 *
15.4 x
P/E ratio 2025 *
13.5 x
Employees 71,000
Yield 2024 *
2.64%
Yield 2025 *
2.8%
Free-Float 70.76%
More Fundamentals * Assessed data
Dynamic Chart
Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time RE
Merck: promising new results for Keytruda CF
Global markets live: Adobe, Ulta Beauty, Intel, Walt Disney, McDonald's... Our Logo
Old demons return as tech takes a dive Our Logo
Merck Says Late-Stage Trial for Keytruda Regimen Meets Primary Endpoint in Patients With Cervical Cancer MT
Merck Announces its KEYTRUDA Plus Chemoradiotherapy Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer CI
Merck to launch new HPV vaccine CF
Merck to Launch Clinical Development of New Potential HPV Vaccine MT
Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus Vaccine and Single-Dose Regimen for GARDASIL®9 CI
Merck to test single-dose regimen of HPV vaccine Gardasil 9 RE
Transcript : Merck & Co., Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM
Global markets live: Domino's Pizza, Generali, Oracle, Intel, Boeing... Our Logo
IDEAYA Biosciences, Merck Sign Deal to Evaluate IDE161 in Combination with Keytruda to Treat Endometrial Cancer Patients MT
IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer CI
Moderna, Merck to Begin Phase 2/3 Study of V940 Plus Pembrolizumab in Skin Cancer MT
More news
1 day-0.07%
1 week-1.67%
Current month-4.49%
1 month-4.97%
3 months+15.54%
6 months+12.95%
Current year+11.39%
More quotes
1 week
119.23
Extreme 119.23
123.21
1 month
119.23
Extreme 119.23
130.24
Current year
109.16
Extreme 109.16
130.24
1 year
99.14
Extreme 99.14
130.24
3 years
70.89
Extreme 70.89
130.24
5 years
65.25
Extreme 65.25
130.24
10 years
45.69
Extreme 45.69
130.24
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Director of Finance/CFO 55 89-12-31
Chief Tech/Sci/R&D Officer 55 20-07-31
Members of the board TitleAgeSince
Director/Board Member 63 07-11-26
Director/Board Member 66 15-08-31
Director/Board Member 69 18-02-28
More insiders
Date Price Change Volume
24-03-18 121.4 -0.07% 8,311,895
24-03-15 121.5 +0.84% 46,477,417
24-03-14 120.5 -1.35% 10,132,544
24-03-13 122.2 -0.41% 9,186,104
24-03-12 122.7 -0.09% 11,621,795

Delayed Quote Nyse, March 18, 2024 at 04:01 pm EDT

More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
121.4 USD
Average target price
134.3 USD
Spread / Average Target
+10.56%
Consensus
  1. Stock
  2. Equities
  3. Stock Merck & Co., Inc. - Nyse